Authors' objectives: Chronic lymphocytic leukaemia is a cancer which usually develops very slowly. In people with chronic lymphocytic leukaemia, the body makes too many white blood cells called lymphocytes. These lymphocytes are abnormal and do not work properly so build up in the lymph nodes (glands) and bone marrow. Idelalisib is a new type of drug for patients with chronic lymphocytic leukaemia who have not yet received any treatment. It is given as a tablet taken twice a day. Some studies have suggested that idelalisib may work best in combination with two drugs that are already used for the treatment of this disease, bendamustine and rituximab. If idelalisib is licensed for use in the UK, it could be a new treatment option for patients with chronic lymphocytic leukaemia that may reduce symptoms of the disease and increase survival.

Project Status: Completed

Year Published: 2015

URL for published report: http://www.hsric.nihr.ac.uk/topics/idelalisib-zydelig-with-bendamustine-and-rituximab-for-chronic-lymphocytic-leukaemia-first-line/

English language abstract: An English language summary is available

Publication Type: Not Assigned

Country: England, United Kingdom

Organisation Name: NIHR Horizon Scanning Centre

Contact Address: The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269

Contact Name: c.packer@bham.ac.uk

Contact Email: c.packer@bham.ac.uk

Copyright: NIHR Horizon Scanning Centre (NIHR HSC)